Protagenic Therapeutics Inc (NASDAQ: PTIX)’s stock price has dropped by -13.29 in relation to previous closing price of 0.22. Nevertheless, the company has seen a loss of -25.22% in its stock price over the last five trading days. accesswire.com reported 2024-11-05 that NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) (“Protagenic Therapeutics” or the “Company”), a leader in biopharmaceutical innovation, announced today that on November 4, 2024 it closed its previously announced private placement pursuant to a purchase agreement (the “Purchase Agreement”) for the purchase and sale of an aggregate of 1,948,295 shares of common stock, series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date, and series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. The purchase price of each share of common stock and associated common stock purchase warrants was $0.64 ($0.89 in the case of insiders).
Is It Worth Investing in Protagenic Therapeutics Inc (NASDAQ: PTIX) Right Now?
Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PTIX is 6.27M and currently, short sellers hold a 2.96% of that float. On April 01, 2025, PTIX’s average trading volume was 2.08M shares.
PTIX’s Market Performance
PTIX stock saw a decrease of -25.22% in the past week, with a monthly decline of -36.03% and a quarterly a decrease of -63.34%. The volatility ratio for the week is 7.77%, and the volatility levels for the last 30 days are 14.72% for Protagenic Therapeutics Inc (PTIX). The simple moving average for the past 20 days is -29.52% for PTIX’s stock, with a -65.99% simple moving average for the past 200 days.
PTIX Trading at -36.83% from the 50-Day Moving Average
After a stumble in the market that brought PTIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.57% of loss for the given period.
Volatility was left at 14.72%, however, over the last 30 days, the volatility rate increased by 7.77%, as shares sank -30.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -56.45% lower at present.
During the last 5 trading sessions, PTIX fell by -25.22%, which changed the moving average for the period of 200-days by -79.78% in comparison to the 20-day moving average, which settled at $0.2768. In addition, Protagenic Therapeutics Inc saw -60.18% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PTIX
Current profitability levels for the company are sitting at:
- -185.94 for the present operating margin
- -0.83 for the gross margin
The net margin for Protagenic Therapeutics Inc stands at -199.27. The total capital return value is set at -7.33. Equity return is now at value -231.87, with -162.74 for asset returns.
Currently, EBITDA for the company is -5.7 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 12.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.80.
Conclusion
To wrap up, the performance of Protagenic Therapeutics Inc (PTIX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
